Compare AbCellera Biologics Inc (ABCL) vs LYFT Inc (LYFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs LYFT Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while LYFT Inc trades at $15.05 (market cap $5.86B). The key difference: LYFT Inc is far larger — about 2.5× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | LYFT | |
|---|---|---|
Market Cap | $2.35B | $5.86B |
Sector | Health | Industrials |
52-Week High | $8.12 | $24.57 |
52-Week Low | $2.78 | $12.65 |
Enterprise Value | $1.99B | $5.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Lyft trades at $15.44, up 0.46% today, with a bullish technical signal from moving averages and oscillators. The company shows strong profitability with 43.82% net income margin and robust cash flow generation of $1.17B from operations in 2025. Recent management changes include the appointment of Senthil Padmanabhan as CTO effective July 2026, signaling continued operational focus.
Lyft presents an attractive valuation with P/E of 2.25 and P/S of 0.97, trading below the $18.25 consensus price target. However, mixed earnings performance and competitive pressures from Uber require monitoring. The stock offers upside potential but faces execution risks in the evolving ridesharing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
